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easonal influenza epidemics cause worldwide morbidity and mortality (1), whereas the vast reservoir of influenza A viruses in aquatic birds represents continual pandemic threats (2) (3) (4) . Vaccines remain essential for influenza prevention, but their efficacy is substantially reduced in the elderly, who are at increased risk of influenza-related complications (3, 5, 6) . Annual selection of vaccine strains presents many challenges, and a poor match with circulating viruses can result in suboptimal effectiveness (7) . Moreover, most vaccine-induced antibodies are directed against the highly variable head region of hemagglutinin (HA) and are strain specific. However, broadly neutralizing antibodies (bnAbs) targeting influenza HA have been isolated and characterized (8) . Several bnAbs have entered clinical trials as therapeutic agents, but their use in influenza prophylaxis remains elusive because of the incomplete coverage against circulating human influenza A and B viruses, which necessitates administration of a bnAb cocktail, and the need for multiple, high-dose injections for protection throughout the entire influenza season. High serum bnAb levels are required because of poor distribution to the upper airways. We present an alternative strategy for long-lasting protection in which single-domain antibodies (sdAbs) (9) with influenza A or B reactivity are linked together into a multidomain antibody (MDAb) and expressed at the nasopharyngeal mucosa through the intranasal administration of a recombinant adeno-associated virus (AAV) vector (10, 11) encoding the MDAb transgene.
Broadly neutralizing sdAbs were obtained by immunizing llamas with influenza vaccine and H7 and H2 recombinant HA (rHA) (12) . HA crossreactive sdAbs were isolated from the sdAb [the single variable domain of a heavy-chain-only camelid antibody (V H H)] repertoires of the immunized llamas by phage display with various cross-selection strategies on rHAs from different influenza subtypes. We isolated two influenza A (SD36 and SD38) and two influenza B (SD83 and SD84) sdAbs and analyzed their in vitro neutralizing activity (Fig. 1) . SD36 potently neutralized influenza A group 2 (H3, H4, H7, and 1 of 5 Fig. 1 . In vitro neutralization of influenza A and B viruses by individual and genetically fused sdAbs. In vitro potencies of SD36, SD38, SD83, and SD84 and genetically fused sdAbs SD38-SD36 and SD83-SD84 against selected influenza A and B viruses. Both SD38-SD36 and SD83-SD84 are significantly more potent (*P < 0.05) than each of their individual components (comparisons are shown via brackets) (see materials and methods in the supplementary materials). Data are representative of at least three independent experiments performed in quadruplicate. H10) but not group 1 (H1, H2, and H5) viruses, whereas SD38 potently neutralized group 1 (H1, H2, and H5) and some group 2 (H3, H7, and H10) viruses, albeit with lower potency. SD84 and SD83 neutralized representative viruses from both influenza B lineages. To elucidate the molecular basis for the broad HA recognition, we determined the crystal structures of SD38 and SD83 to 2.0-Å resolution; SD36, SD38, and SD83 with different HAs to 2.2 to 2.8 Å; humanized SD84 (SD84h) to 0.94 Å; and SD84h with HA (B/Brisbane/60/08) and bnAb CR9114 to 4.1 Å (13) (Fig. 2 and table S1 ). A cryo-electron microscopy (EM) reconstruction of SD84 with B/Massachusetts/02/12 HA and CR9114 was determined to 7.1-Å resolution ( fig. S1 ). All sdAbs except SD84 recognized the HA stem, with three sdAbs bound per trimer (Fig. 2) . SD83 contacted conserved residues in the fusion subdomain ( Fig. 2A) Fig. 2A) . The SD83 epitope was highly conserved, with all contact residues being >99% identical in influenza B viruses ( Fig. 2A and table S2 ). SD83 buried a relatively small surface area (588 Å 2 ) on HA, which potentially presented fewer possibilities for escape. In contrast, SD84 bound a conserved epitope in the HA head around the receptor binding site (Fig. 2B and table S2 ). SD36 and SD38 also recognized conserved epitopes that partially overlap with influenza A stem epitopes of bnAbs CR9114, CR6261, and FI6v3 and, to a lesser extent, those of CR8043 and CR8020 (13) (14) (15) (16) (17) .
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Thus, SD38 and SD36 made extensive contacts to the A helix and other highly conserved residues (tables S3 and S4). However, 33% of H3 viruses had an Asp 46 →Asn (D46N) polymorphism and were not neutralized by SD36 (table S5) (IC 50 ) >1 mM]. As all group 1 viruses were glycosylated at HA1 N289, steric hindrance may have lowered the SD36 affinity below the neutralization threshold, whereas SD38 avoided this glycan (table S6) . HA2 Val 18 and Leu 38 on the SD38 epitope periphery were the least conserved across H1 strains (table S3 and Fig. 2D ), but natural mutations Gln 38 or Ile 18 and Gln 38 did not affect neutralization (table S7) .
We next rationalized that linking different sdAbs could generate MDAbs with increased potency and breadth. Thus, MDAbs were engineered by genetically fusing individual sdAbs with peptide linkers and then linking them to human immunoglobulin G1 (IgG1) Fc (Fig. 3) . The SD38-SD36 fusion was generally more potent, with broader cross-reactivity, than SD36 and SD38 alone, especially against H3 viruses (Fig. 1) . Notably, SD38-SD36 neutralized D46N-carrying H3N2 viruses A/Panama/2007/99 and A/Wisconsin/ 67/05, neither of which was neutralized by SD36 or SD38, thereby demonstrating a synergistic effect (table S8) . SD83-SD84 also neutralized influenza B viruses much more potently, especially B/Lee/40 (Fig. 1) . Notably, MD2407 (SD38-SD36-SD83-SD84) and MD3606 (MD2407 fused to human IgG1 Fc) neutralized all A (H1 to H12 and H14) and B viruses tested except for one avian H12 virus (18) and had much greater breadth and potency than the individual sdAbs or CR9114 (Fig. 3 and table S9 ). MD3606 also strongly bound avian H13, H15, and H16 and bat H17 and H18 HAs (table S6) .
Depending on their epitopes, known bnAbs inhibit influenza infection by blocking viral attachment, HA proteolytic activation, membrane fusion, or viral egress (19) (20) (21) . The HA headbinding SD84 and both MDAbs inhibited hemagglutination by influenza B (B/Florida/04/ 06-MA) virus (table S10). All three stem binders and both MDAbs blocked the low-pH HA rearrangements required for membrane fusion ( fig. S5 ). Unlike CR8020, the sdAbs or MDAbs could not prevent HA proteolytic activation (HA0 to HA1 and HA2), reflecting their epitope location further up the HA stem (figs. S2 and S6). In contrast to SD83 and SD84, MD2407 and MD3606 inhibited egress of B/Malaysia/2506/04 virus ( fig. S7 ), similar to some other bnAbs (21, 22) .
A shift from monovalency (Fab) to bivalency (IgG) can considerably increase the binding and neutralization breadth of influenza A antibodies, mainly to the HA head (23) (24) (25) . We extended this concept with our MDAbs that targeted different HA conserved epitopes, resulting in greatly increased potency and unparalleled neutralization breadth. From our crystal and EM structures, we were able to exclude simultaneous binding of the MDAbs to epitopes on the same HA trimer ( fig. S8A and table S11) (26) . MDAbs could also increase avidity through cross-linking adjacent HA trimers on the viral surface. Inter-crosslinked HA complexes (85 to 96 Å) were indeed visible in negative-stain EM ( fig. S8B ). If this holds for HA trimers on the viral surface, it could partially explain the increased potency of MD2407 and MD3606 versus their individual sdAb components.
To assess in vivo protection, we compared the prophylactic efficacy of MD3606 with that of CR9114 and CR8071 in BALB/c mice challenged with H1N1, H3N2, H7N9, and B viruses by using intravenous administration (Fig. 4, A to D, and figs. S9 and S10). MD3606 at 1.7 mg per kilogram of body weight completely protected mice from a lethal dose of mouse-adapted H1N1 virus (A/Puerto Rico/8/34-MA) and was superior to CR9114 at 5 mg/kg. MD3606 at 5 mg/kg provided complete protection from H3N2 virus (A/Hong Kong/1/68-MA) infection, whereas at 1.7 mg/kg, seven of eight mice survived with MD3606, compared with five of eight with CR9114. With an H7N9 virus (A/Anhui/1/13), mice were completely protected with MD3606 at 5 mg/kg versus 15 mg/kg for CR9114. Finally, at 1 mg/kg, MD3606 protected all mice from influenza B virus (B/ Florida/4/06-MA) infection and was superior to CR9114 and CR8071 (12.5 and 50% survival). MD3606 administered 1 day before challenge with H1N1 or B virus also resulted in a dosedependent reduction in lung viral load ( fig. S11) .
Antibody-dependent cellular cytotoxicity (ADCC) can also contribute to in vivo bnAb efficacy (27) . In an ADCC reporter assay, MD3606 activated H1  H2  H5  H6  H8  H9  H11  H12  H3  H4  H7  H10  H14  B   1   10   100   >1000   H1  H2  H5  H6  H8  H9  H11  H12  H3  H4  H7  H10  H14  B   1   10   100   >1000   H1  H2  H5  H6  H8  H9  H11  H12  H3  H4  H7  H10  H14  B   1   10   100   >1000   MD2407  MD3606  CR9114   38  36  83  84   38  36  83  84   38  36  83  84 C H 2 C H 3 We then evaluated the prophylactic efficacy of a recombinant AAV9 vector encoding humanized MD3606 (29) (AAV9.MD3606h) in mice challenged with mouse-adapted influenza H1N1, H3N2, and B viruses (Fig. 4, E to G, and fig. S14 ). AAV9.MD3606h was administered intranasally 7 days before influenza challenge at vector doses ranging from 4 × 10 7 to 5 × 10 9 genome copies (GCs) per mouse. A dose of 5 × 10 9 GCs completely protected against lethal challenge with H1N1 virus (A/Puerto Rico/8/34-MA), whereas seven of eight mice survived with a dose of 1 × 10 9 GCs. Mice challenged with H3N2 (A/Hong Kong/1/68-MA) and B (B/Lee/40-MA) viruses were fully protected by intranasal administration of 5 × 10 8 GCs (the lowest dose tested) and 1 × 10 9 GCs, respectively. AAV9.MD3606h also conferred protection against H1N1 virus when administered 35 days before challenge ( fig. S15 ). Preexisting serum-circulating AAV9-specific neutralizing antibodies did not affect the prophylactic efficacy of AAV9.MD3606h ( fig. S16) .
Limitations of seasonal influenza vaccines, together with the constant threat of a new influenza pandemic, have spurred the search for new influenza prevention strategies. One such strategy involves passive immunization by AAVmediated delivery of genes encoding protective bnAbs (11) . In preclinical mouse models, intranasal delivery of AAV9 encoding bnAb FI6 provided protection against H1N1 infection 3 days after vector administration (11) . Notably, old and immunodeficient mice were also protected from a lethal H1N1 dose (10) . Mucosal expression of the AAV9 transgene is durable [>9 months in mice (30) and 4 months in rhesus macaques (11) ], and AAV9 vectors can be readministered in the airway without loss of efficiency (30) . To be clinically useful, AAV-encoded bnAbs should neutralize both influenza A and B viruses, but all bnAbs to date lack sufficient influenza A and B cross-reactivity; the limited AAV packaging capacity (<5 kb) also precludes the expression of two individual bnAbs or a bispecific bnAb from a single vector. We used an alternative antibody platform with camelidderived sdAbs to create two highly potent MDAbs, MD3606 and MD2407, which have near-universal activity against influenza A and B viruses and can both be expressed from a single AAV vector. Fc-containing MD3606 administered intravenously was more effective than state-of-theart bnAb CR9114 against seasonal and pandemic influenza viruses, with a significant effect (P < 0.05) on survival in H7N9 and B models (table S12). Intranasal delivery of AAV9.MD3606h provided full protection in mice at doses as low as 5 × 10 8 GCs. If the above preclinical findings translate to humans, an annual intranasal administration of AAV9.MD3606h may provide passive protection for the entire influenza season and would be of particular benefit to the elderly and other high-risk groups. The rapid onset of protection, together with the unprecedented cross-reactivity of MD3606 to avian influenza strains, also offers the possibility of using this approach as a prophylactic immediately upon onset of an influenza pandemic, providing substantial advantages over vaccination. 
